Document:

Exhibit 10.1 Q3'13

Exhibit 10.1

July 17, 2013                

To: Keith Sullivan

Re: Promotion

Dear Keith:

The purpose of this letter is to outline the details of your promotion with ZELTIQ Aesthetics Inc. (the “Company”).  Upon acceptance by you, this letter shall constitute an agreed upon understanding between you and the Company.  Unless specifically listed below, all other aspects of your employment with the Company shall remain unchanged.

		
	Effective Date:
	This new position is effective July 17, 2013.

		
	Position:
	Senior Vice President of Worldwide Sales and Marketing, reporting to Mark Foley, President and Chief Executive Officer

		
	Compensation: 
	There is no change to your base salary or bonus participation at this time.

		
	Equity:
	Subject to the approval of the Company’s Board of Directors, you will be granted an option to acquire an additional 30,000 (thirty thousand) shares of Common Stock of the Company pursuant to the Company’s 2011 Equity Plan. The exercise price will be equal to the closing trading price of the Company’s Common Stock on July 17, 2013.  This option will become exercisable (vest) over a four-year period with one-fourth (1/4th) of the options vesting at the end of twelve months, and the remainder vesting monthly at a rate of 1/36th of the remaining number per month thereafter until all shares are vested. The options will be subject to the terms and conditions applicable to options granted under the Company’s 2011 Equity Incentive Plan, and as described in that plan and the applicable equity agreement.

		
	Employment At Will:
	All Zeltiq employees are employed on an “at-will” basis.  Your employment with the Company is voluntarily entered into and is for no specified period.  As a result, you are free to resign at any time, for any reason or for no reason, as you deem appropriate.  The Company will have a similar right and may conclude its employment relationship with you at any time, with or without cause.

Congratulations and thank you for your ongoing contributions to the Company.  

Sincerely,

/s/ Mark J. Foley                         
Mark Foley, President & CEO

Agreed to and accepted:

/s/ Keith Sullivan                         
Keith Sullivan
Dated:  August 06, 2013Exhibit 10.2 Q3'13

Exhibit 10.2

Purpose:

The 2013 Corporate Bonus Plan, as amended (the “Bonus Plan”), establishes a corporate incentive for all eligible employees upon the achievement of the 2013 Corporate Objective as defined below.  The bonus is designed to provide employees with a performance incentive to align departments and individual employees to achieve the revenue target for the plan year.

Effective Date:  January 1, 2013-December 31, 2013

Eligibility:

All regular, full-time employees of ZELTIQ, Inc. and ZELTIQ, Ltd. are eligible for participation as long as:

		
	•
	Employment begins prior to October 1, 2013;

		
	•
	Employment continues through Payment Date, and

		
	•
	Employees are not a participant in a variable commission plan*.

*Employees participating in a variable commission plan are not eligible to participate in the Bonus Plan.  Such employees include, but are not limited to: Account Managers, Regional Sales Directors, Practice Support Specialists, Regional, Practice Managers, Inside Sales and Managing Director of Practice Support.

Earned Date:

No Bonus is guaranteed and must be earned.  The bonus is considered earned under this Bonus Plan at Payment Date.

Payment Date:

If the Corporate Objective has been met, all eligible employees will receive a bonus on or about February 15, 2014.

Corporate Objective and Bonus Payout Calculation:

The Corporate Objective is defined as follows:

FY13 WW Revenue of an amount established by the Board, and Cash Burn of an amount established by the Board.

Achievement of the Corporate Objective will result in a 100% Bonus Payout.

The Bonus Payout is based on each employee target bonus % (as described below under Participation Levels).

Participation Levels:

Employees are eligible for a target bonus percentage of base salary, based on position or, in the case of Individual Contributors, based on salary.  The designated participation levels for 2013 shall be set by the Compensation Committee.  The CEO may change participation levels for nonexecutive officers and below, and may recommend changes to participation levels for executive officers (except for changes to the CEO participation level), subject to review and approval by the Compensation Committee. 

Pro rata:

The bonus calculation is factored by the length in which an eligible employee has been employed with the Company during the Bonus Plan’s Effective Date.

Termination of Employment:

No bonus is considered earned under this Bonus Plan until the Payment Date.  As a result, an employee who has been terminated (either by the Company or by resignation) will not be entitled to any bonus.

Modification:

This plan is subject to review and modification by the Compensation Committee, at its discretion.PCRX - 9.30.2013 - EX10.1

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE REDACTED PORTIONS OF THIS EXHIBIT.  THE REDACTIONS ARE INDICATED WITH “[**]”.  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION.
LEGAL28169991.1 
Exhibit 10.1
FIRST AMENDMENT TO
COMMERCIAL OUTSOURCING SERVICES AGREEMENT
This First Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between Integrated Commercialization Solutions, Inc. (“ICS”) and Pacira Pharmaceuticals, Inc. (the “Company”). This Amendment is effective as of August 1, 2013 (the “Amendment Effective Date”).
RECITALS
		
	A.
	ICS and the Company are parties to a Commercial Outsourcing Services Agreement dated August 25, 2011 (the “Agreement”);

		
	B.
	Pursuant to the Agreement, among other things, the Company engaged ICS to perform commercialization services for certain pharmaceutical products; and

		
	C.
	The parties now wish to amend the Agreement in certain respects.

AMENDMENT
NOW THEREFORE, the parties agree as follows:
		
	1.
	Defined Terms.  Capitalized terms in this Amendment that are not defined in this Amendment have the meanings given to them in the Agreement. If there is any conflict between the Agreement and any provision of this Amendment, this Amendment will control.

		
	2.
	Schedule B.  The parties agree that Schedule B to the Agreement is hereby deleted in its entirety and replaced with the attached Revised Schedule B.

		
	3.
	No Other Changes.  Except as otherwise provided in this Amendment, the terms and conditions of the Agreement will continue in full force.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the Amendment Effective Date.
Integrated Commercialization Solutions, Inc.        Pacira Pharmaceuticals, Inc.
By:/s/ Stephen McKinnon                    By: /s/ Lauren Riker            
Name: Stephen  McKinnon                Name:     Lauren Riker            
Title: SVP, GM                        Title:  Executive Director            

SCHEDULE B
ICS 3PL SCHEDULE OF FEES
	
			
	Fee
	Amount
	Description

	Monthly Management Fee

	Customer Service
Warehouse & Distribution
Returns Management
Finance
Information Technology & Reporting
Chargeback Management
Sample Management
Marketing Material Management
	$[**]
	 [**]

	Customer Service Fees

	Order Processing Fee
	$[**]

$[**]
	[**]

[**]

	
			
	Customer Setup Fee
	$[**]
	[**]

	Account Maintenance/ License Updates
	$[**]
	[**]

	Allocation Fee
	$[**]
	[**]

	Rush Order
	$[**]
	[**]

	Emergency Order
	$[**]
	[**]

	International Order
	$[**]
	[**]

	Warehouse & Distribution Fees

	Product Storage
	$[**]
	[**]

	Trade Order Processing Fees
	$[**]
$[**]
$[**]
$[**]
+
$[**]
$[**]
$[**]
	[**]
 
[**]

[**]

	Receiving Fee
	$[**]
	[**]

	Shipping Fee
	$[**]
	[**]

	Bulk Shipments
	$[**]
	[**]

	Packing Supplies
	[**]
	[**]

	Freight
	[**]
	[**]

	Finance

	Invoice Processing
	$[**]
	[**]

	Credit Verification Reports
- Dun & Bradstreet
	$[**]
	[**]

	Credit Verifications Reports 
- Experian
	$[**]
	[**]

	Returns Management

	RGA Initiation
	$[**]
+
$[**]
	[**]

[**]

	Return Processing
	$[**]
	[**]

	Partial Returns Processing
	$[**]
	[**]

	Returns Storage
	$[**]
	[**]

	Contract and Chargeback Management

	Chargeback Processing-
Manual
	$[**]
	[**]

	Chargeback Processing-Electronic
	$[**]
	[**]

	Membership Additions
	$[**]
	[**]

	Contract Setup
	$[**]
	[**]

	Contract Updates
	$[**]
	[**]

	Information Technology and Reporting

	852/867: ABC,CAH, MCK
	$[**]
	[**]

	Custom Reports
	$[**]
	[**]

	
			
	Custom Development Services
	$[**]
	[**]

	Additional Fees

	Product Destruction
	[**]
	[**]

	Telecom
	[**]
	[**]

	FedEx/UPS/Postage Expenses
	[**]
	[**]

	Pre-Approved Assessorial Labor Charge-Warehouse
	$[**]
	[**]

	Pre-Approved Assessorial Labor Charge-Office Staff
	$[**]
	[**]

	Pre-Approved Assessorial  Labor Charge-QC,  Management
	$[**]
	[**]

	ICS Travel
	[**]
	[**]PCRX - 9.30.2013 - EX10.2

Exhibit 10.2
AMENDMENT #3 TO SERVICES AGREEMENT
This Amendment #3 to Services Agreement (this “Amendment”), is entered into as of September 11, 2013, by and between Pacira Pharmaceuticals, Inc., (the “Company”), MPM Asset Management LLC (“MPM”) and Gary Patou (“Consultant”).
This Amendment #3 amends the Services Agreement dated October 28, 2010 by and among the Company, MPM and Consultant, as amended on December 8, 2011 and November 29, 2012 (the “Original Agreement”).  If there is any conflict between the provisions of this Amendment and those in the Original Agreement, the provisions of this Amendment govern.  Except as expressly stated in this Amendment, capitalized terms used and not defined herein have the same meanings defined in the Original Agreement.  Except as expressly amended herein, all other terms and provision of the Original Agreement remain in full force and effect.
RECITALS
A.    Consultant currently devotes approximately 50% of his business time to the Company for a monthly service fee of $15,880.40.  The parties desire to amend the terms so Consultant will devote approximately 80% of his business time to the Company for a monthly service fee of $26,467.33 through December 31, 2014.
AGREEMENT
NOW, THEREFORE, in consideration of the representations, warranties and agreements contained in this Agreement and other good and valuable consideration, the receipt of which is hereby acknowledged, the Parties agree as follows:
1.    Section 4(a) is hereby amended to reflect that the amount of Monthly Services Fee is $26,467.33 through December 31, 2014.
2.    Exhibit A is hereby amended to reflect that Consultant shall devote approximately 80% of his business time to the Company through December 31, 2014.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written.

PACIRA PHARMACEUTICALS, INC.
By:  /s/ Dave Stack__________
Dave Stack
President Chief Executive Officer
MPM ASSET MANAGEMENT LLC
By:  /s/ Luke Evnin___________
Luke Evnin
Managing Director

CONSULTANT

/s/ Dr. Gary Patou_____________
Dr. Gary Patou

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]